

REMARKS

Claims 1-22 have been canceled, without prejudice. Claims 23-44 are pending. Support for the pending claims can be found throughout the specification. No new matter has been added.

The specification has been amended to include a cross-reference to the parent application.

The attached paper and computer readable copies of the Sequence Listing are the same. No new matter has been added.

Return of an initialed copy of the attached Form PTO/SB/08a is requested.

Acknowledgement of receipt of the priority document from the IB is requested.

Acceptance of the attached formal drawings is requested.

An early and favorable Action on the merits of the claimed invention is requested.

Respectfully submitted,
NIXON & VANDERHYE P.C.
By: /B. J. Sadoff/

B. J. Sadoff
Reg. No. 36,663

BJS:alb

901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

10/579921

SEQUENCE LISTING

1AP20 Rec'd PCT/PTO 19 MAY 2006

<110> University Paris 13, CNRS

<120> PEPTIDE INCREASING FUSIOGENIC CAPACITY OF A GAMETE

<130> 3665-180

<140> Unassigned

<141> 2006-05-19

<150> PCT/FR2004/002956

<151> 2004-11-19

<150> FR 03 13545

<151> 2003-11-19

<160> 9

<170> PatentIn version 3.1

<210> 1

<211> 30

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (14)..(16)

<223> Tripeptide

<400> 1

Cys Leu Phe Met Ser Lys Glu Arg Met Cys Arg Pro Ser Phe Glu Glu
1 5 10 15

Cys Asp Leu Pro Glu Tyr Cys Asn Gly Ser Ser Ala Ser Cys
20 25 30

<210> 2

<211> 30

<212> PRT

<213> *Mus musculus*

<220>

<221> SITE

<222> (14)..(16)

<223> Tripeptide

<400> 2

Cys Lys Leu Lys Arg Lys Glu Val Cys Arg Leu Ala Gln Asp Glu
1 5 10 15

Cys Asp Val Thr Glu Tyr Cys Asn Gly Thr Ser Glu Val Cys
20 25 30

<210> 3

<211> 30

<212> PRT

<213> *Cavia porcellus*

<220>

<221> SITE

<222> (14)..(16)

<223> Tripeptide

> <400> 3

Cys Glu Phe Lys Thr Lys Gly Glu Val Cys Arg Glu Ser Thr Asp Glu
1 5 10 15

Cys Asp Leu Pro Glu Tyr Cys Asn Gly Ser Ser Gly Ala Cys
20 25 30

<210> 4

<211> 30

<212> PRT

<213> Oryctolagus cuniculus

<220>

<221> SITE

<222> (14)..(16)

<223> Tripeptide

<400> 4

Cys Thr Phe Lys Glu Arg Gly Gln Ser Cys Arg Pro Pro Val Gly Glu
1 5 10 15

Cys Asp Leu Phe Glu Tyr Cys Asn Gly Thr Ser Ala Leu Cys
20 25 30

<210> 5

<211> 30

<212> PRT

<213> Macaca fascicularis

<220>

<221> SITE

<222> (14)..(16)

<223> Tripeptide

<400> 5

Cys Leu Phe Met Ser Gln Glu Arg Cys Cys Arg Pro Ser Phe Asp Glu
1 5 10 15

Cys Asp Leu Pro Glu Tyr Cys Asn Gly Thr Ser Ala Ser Cys
20 25 30

<210> 6

<211> 30

<212> PRT

<213> Bos taurus

<220>

<221> SITE

<222> (14)..(16)

<223> Tripeptide

<400> 6

Cys Ala Phe Ile Pro Lys Gly His Ile Cys Arg Gly Ser Thr Asp Glu
1 5 10 15

Cys Asp Leu His Glu Tyr Cys Asn Gly Ser Ser Ala Ala Cys
20 25 30

<210> 7

<211> 30

<212> PRT

<213> Rattus norvegicus

<220>

<221> SITE

<222> (14)..(16)

<223> Tripeptide

<400> 7

Cys Asn Leu Lys Ala Lys Gly Glu Leu Cys Arg Pro Ala Asn Gln Glu
1 5 10 15

Cys Asp Val Thr Glu Tyr Cys Asn Gly Thr Ser Glu Val Cys
20 25 30

<210> 8

<211> 30

<212> PRT

<213> Sus scrofa

<220>

<221> SITE

<222> (14)..(16)

<223> Tripeptide

<400> 8

Cys Ser Phe Met Ala Lys Gly Gln Thr Cys Arg Leu Thr Leu Asp Glu
1 5 10 15

Cys Asp Leu Leu Glu Tyr Cys Asn Gly Ser Ser Ala Ala Cys
20 25 30

<210> 9

<211> 6

<212> PRT

<213> artificial sequence

<220>

<223> peptide FEEC

<220>

<221> SITE

<222> (1) .. (6)

<223> DISULFIDE

<400> 9

Cys Ser Phe Glu Glu Cys
1 5